BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp Buys 9,234 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp lifted its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 61.6% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 24,217 shares of the biopharmaceutical company’s stock after acquiring an additional 9,234 shares during the quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp’s holdings in Alnylam Pharmaceuticals were worth $5,885,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Allspring Global Investments Holdings LLC increased its position in Alnylam Pharmaceuticals by 572.0% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 168 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 143 shares during the period. Ashton Thomas Private Wealth LLC acquired a new stake in shares of Alnylam Pharmaceuticals during the second quarter worth $26,000. Altitude Crest Partners Inc. acquired a new stake in shares of Alnylam Pharmaceuticals during the first quarter worth $30,000. V Square Quantitative Management LLC bought a new position in Alnylam Pharmaceuticals during the fourth quarter worth $52,000. Finally, Prestige Wealth Management Group LLC lifted its holdings in Alnylam Pharmaceuticals by 69.8% in the first quarter. Prestige Wealth Management Group LLC now owns 472 shares of the biopharmaceutical company’s stock valued at $71,000 after buying an additional 194 shares during the period. 92.97% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Alnylam Pharmaceuticals news, CEO Yvonne Greenstreet sold 7,093 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Thursday, July 11th. The shares were sold at an average price of $261.00, for a total transaction of $1,851,273.00. Following the transaction, the chief executive officer now owns 73,441 shares of the company’s stock, valued at approximately $19,168,101. The transaction was disclosed in a legal filing with the SEC, which is available through this link. In other Alnylam Pharmaceuticals news, Director Dennis A. Ausiello sold 20,250 shares of the company’s stock in a transaction on Tuesday, August 6th. The stock was sold at an average price of $262.00, for a total value of $5,305,500.00. Following the completion of the transaction, the director now owns 136 shares in the company, valued at approximately $35,632. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Yvonne Greenstreet sold 7,093 shares of the firm’s stock in a transaction on Thursday, July 11th. The shares were sold at an average price of $261.00, for a total value of $1,851,273.00. Following the sale, the chief executive officer now directly owns 73,441 shares of the company’s stock, valued at $19,168,101. The disclosure for this sale can be found here. In the last ninety days, insiders sold 57,491 shares of company stock valued at $15,446,733. Corporate insiders own 1.50% of the company’s stock.

Alnylam Pharmaceuticals Stock Up 0.7 %

Shares of NASDAQ:ALNY opened at $274.57 on Friday. The business’s 50 day moving average is $262.26 and its 200 day moving average is $202.14. Alnylam Pharmaceuticals, Inc. has a 12-month low of $141.98 and a 12-month high of $287.55. The stock has a market cap of $34.73 billion, a price-to-earnings ratio of -102.45 and a beta of 0.38.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its earnings results on Thursday, August 1st. The biopharmaceutical company reported ($0.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.74) by $0.61. The firm had revenue of $659.83 million during the quarter, compared to the consensus estimate of $447.22 million. The business’s revenue was up 107.0% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($2.21) EPS. As a group, equities research analysts expect that Alnylam Pharmaceuticals, Inc. will post -2.73 earnings per share for the current year.

Wall Street Analysts Forecast Growth

ALNY has been the subject of a number of recent analyst reports. Canaccord Genuity Group increased their price target on Alnylam Pharmaceuticals from $357.00 to $366.00 and gave the stock a “buy” rating in a report on Friday, August 2nd. Morgan Stanley lifted their target price on Alnylam Pharmaceuticals from $250.00 to $255.00 and gave the stock an “equal weight” rating in a report on Friday, July 12th. BMO Capital Markets reissued an “outperform” rating and issued a $234.00 price target on shares of Alnylam Pharmaceuticals in a research note on Monday, June 24th. HC Wainwright reaffirmed a “buy” rating and set a $400.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Friday, August 30th. Finally, Leerink Partners boosted their target price on shares of Alnylam Pharmaceuticals from $138.00 to $159.00 and gave the company a “market perform” rating in a research report on Tuesday, June 25th. Seven analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company’s stock. Based on data from MarketBeat, Alnylam Pharmaceuticals has an average rating of “Moderate Buy” and a consensus target price of $279.14.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.